Insightec vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
Insightec is an Israeli medtech company founded in 1999 with $574M+ raised; its Exablate Neuro platform received FDA approval for bilateral Parkinson's disease treatment in July 2025;
About
Insightec is a privately held medical device company founded in 1999 and headquartered in Tirat Carmel, Israel, with offices in Dallas, Miami, Shanghai, and Tokyo. The company pioneered MR-guided focused ultrasound (MRgFUS) technology — a non-invasive surgical modality that uses focused acoustic energy guided in real time by magnetic resonance imaging to precisely destroy deep tissue targets within the body without incisions, radiation, or anesthesia. The technology achieves sub-millimeter precision while MRI provides continuous temperature monitoring to ensure safety and efficacy throughout each treatment.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.